Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms Vaccimil
- 29 Sep 2017 Planned End Date changed from 1 Nov 2015 to 31 Dec 2017.
- 29 Sep 2017 Planned primary completion date changed from 1 Nov 2015 to 31 Dec 2017.
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.